Menu
Search
|

Menu

Close
X

Eloxx Pharmaceuticals Inc ELOX.OQ (NASDAQ Stock Exchange Global Market)

9.20 USD
-- (--)
As of Jul 18
Previous Close 9.20
Open --
Volume --
3m Avg Volume 26,790
Today’s High --
Today’s Low --
52 Week High 18.48
52 Week Low 8.56
Shares Outstanding (mil) 26.92
Market Capitalization (mil) 7.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.332
FY18
-1.449
FY17
-8.674
FY16
-8.278
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
--
7.92
Price to Book (MRQ)
vs sector
2.94
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
9.94
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-66.04
14.49
Return on Equity (TTM)
vs sector
-121.22
15.79

EXECUTIVE LEADERSHIP

Robert Ward
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $452,885.00
Bonus: --
Gregory Weaver
Chief Financial Officer, Since 2017
Salary: $347,212.00
Bonus: --
Gregory Williams
Chief Operating Officer, Since 2018
Salary: $244,712.00
Bonus: $50,000.00
Neil Belloff
Executive Vice President, General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --
David Snow
Chief Business Officer, Since 2018
Salary: $197,460.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1858.9090749

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

SPONSORED STORIES